This article is more than 5 years old. Information may no longer be current.
Two-year data promising for drug-eluting stent
Dake M. Presented at: 2011 International Symposium on Endovascular Therapy; Jan. 16-20; Miami Beach.
Click Here to Manage Email Alerts
Patients treated with a drug-eluting stent had improved patency rate at 2 years, as well as patient safety, when compared with percutaneous transluminal angioplasty, according to data from a prospective, randomized trial.
The study, which was recently presented at the International Symposium on Endovascular Therapy, included 479 patients who were treated with either a paclitaxel-coated drug-eluting stent (Zilver PTX, Cook Medical; n=241) or percutaneous transluminal angioplasty (n=238). Among the risk factors patients presented with included hypertension (drug-eluting stent, 89% vs. percutaneous transluminal angioplasty, 82%), high cholesterol (drug-eluting stent, 76% vs. percutaneous transluminal angioplasty, 70%) and diabetes (drug-eluting stent, 49% vs. percutaneous transluminal angioplasty, 42%).
At 2 years, event-free survival was 86.6% in the drug-eluting stent group vs. 77.6% in the percutaneous transluminal angioplasty arm (P<.01). Primary patency was significantly improved in the drug-eluting stent arm (74.8% vs. 51.8%; P<.01), as was provisional patency (81.2% vs. 62.7%; P<.01). Researchers also reported that the drug-eluting stent reduced 24-month restenosis rates by 50% (37.3% vs. 18.8%).
“This 24-month data is important because it shows not only sustained effect of the drug-eluting platform, but an actual widening of the reductions between the drug-eluting stent and the bare metal stent,” Michael D. Dake, MD, with the department of cardiothoracic surgery at Stanford University School of Medicine and researcher on the study, told Cardiology Today.
The trial was sponsored by Cook Medical.
Disclosure: Dr. Dake reports having consulted for Cook Medical.
 |
Follow CardiologyToday.com on Twitter. |